Acadia pharmaceuticals hosts inaugural r&d day showcasing pipeline and long-term value drivers

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) will host its inaugural 2025 r&d day today to highlight its key pipeline programs and their potential to drive long-term growth. across nine disclosed programs, the company anticipates initiating seven phase 2 or phase 3 studies during 2025-2026. acadia further anticipates reporting five phase 2 or phase 3 study readouts during 2025-2027—underscoring the breadth of its pipeline and the momentum behind its r&d strateg.
ACAD Ratings Summary
ACAD Quant Ranking